Renaissance Technologies LLC Buys Shares of 100,456 Ginkgo Bioworks Holdings, Inc. $DNA

Renaissance Technologies LLC purchased a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 100,456 shares of the company’s stock, valued at approximately $616,000. Renaissance Technologies LLC owned 0.16% of Ginkgo Bioworks as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DNA. Vanguard Group Inc. increased its holdings in Ginkgo Bioworks by 4.2% in the third quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock valued at $36,166,000 after purchasing an additional 99,379 shares during the last quarter. Legal & General Group Plc boosted its holdings in Ginkgo Bioworks by 7.9% during the third quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock worth $23,458,000 after buying an additional 118,402 shares during the last quarter. Millennium Management LLC boosted its holdings in Ginkgo Bioworks by 113.1% during the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock worth $8,137,000 after buying an additional 757,535 shares during the last quarter. State Street Corp boosted its holdings in Ginkgo Bioworks by 38.4% during the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock worth $10,737,000 after buying an additional 358,231 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Ginkgo Bioworks by 23.7% during the 4th quarter. Geode Capital Management LLC now owns 999,600 shares of the company’s stock worth $8,309,000 after buying an additional 191,240 shares during the period. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Trading Up 0.1%

DNA stock opened at $6.80 on Monday. The business’s 50-day moving average price is $8.62 and its two-hundred day moving average price is $8.23. The firm has a market cap of $457.71 million, a PE ratio of -1.36 and a beta of 1.78. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.37 and a 1-year high of $17.58.

Ginkgo Bioworks (NYSE:DNA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.15. Ginkgo Bioworks had a negative return on equity of 60.27% and a negative net margin of 259.96%.The firm had revenue of $20.16 million during the quarter, compared to analysts’ expectations of $24.05 million.

Analyst Ratings Changes

A number of analysts have recently commented on DNA shares. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Friday, July 17th. Finally, TD Cowen cut shares of Ginkgo Bioworks from a “buy” rating to a “hold” rating and decreased their price objective for the company from $12.00 to $9.00 in a report on Friday, August 7th. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of “Sell” and a consensus target price of $7.00.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.